PROGENICS PHARMA INC (PGNX)

Overview Price 9.53 Price Change Today +$0.04 (+0.42%) P&P rating Zacks Rank 3 - HOLD Open Price $9.50 Previous Close $9.49 Daily Range $9.35 - $9.65 52-Week Range $4.50 - $10.50 Volume 110,986 Progenics Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the development & commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward symptom management and supportive care and the treatment of HIV infection and cancer. The Company has four product candidates in clinical development and several others in preclinical development. The Company in collaboration with Wyeth, is developing methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative ileus. In the area of HIV infection, the Company is developing the viral-entry inhibitor PRO one hundred forty, a humanized monoclonal antibody targeting the HIV coreceptor CCR5. In addition, the Company is conducting research on ProVax, a novel prophylactic HIV vaccine. Other Resources for PGNX Detailed Quote Earnings Estimates Company Report Interactive Chart Commentary Zacks Blog: Salix Scores with Oral Relistor December 27, 2011 Zacks Blog: FDA Action Date for Salix's Relistor September 1, 2011 Progenics Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the development & commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward symptom management and supportive care and the treatment of HIV infection and cancer. The Company has four product candidates in clinical development and several others in preclinical development. The Company in collaboration with Wyeth, is developing methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative ileus. In the area of HIV infection, the Company is developing the viral-entry inhibitor PRO one hundred forty, a humanized monoclonal antibody targeting the HIV coreceptor CCR5. In addition, the Company is conducting research on ProVax, a novel prophylactic HIV vaccine.   Brokerage Analyst Recommendations 3 Brokerage Firms Covering PGNX   Strong Buy 2 Buy 1 Hold 0 Sell 0 Strong Sell 0 Average Broker Recommendation (ABR): 1.33   PGNX Ratings: BUY  SELL  HOLD PGNX Consensus Forecasts

Rate this Stock! You haven't rated this stock yet! Ticker Call Buy Sell Analysis Time Frame Week or Less Week to a Month One to Three Months Three to Six Months Six Months to a Year One to Three Years Three Plus Years What The Community Thinks Total Players 15 Buy 0 Sell   Top Buy Analysis BUY: PGNX Company: PROGENICS PHARMACEUTICALS INC. Points: 91.96 Start Price: $4.40 Start Date: 02/03/2010 11:08 AM Gritz06 P&P Score: 53.29 Recs: SMA20 up to upper BB Comments: 0 | Comment More Recent Analysis Top Sell Analysis No Sell Analysis. Be the First. More Recent Analysis

Blog Posts

User	User Score	Date	Title	Comments	Last Comment
Zacks_Analysts	0.00	12/27/11	Salix Scores with Oral Relistor - Analyst Blog	0
Zacks_Analysts	0.00	09/01/11	FDA Action Date for Salix's Relistor - Analyst Blog	0

Commentary

BUY: PROGENICS PHARMACEUTICALS INC. (PGNX) Start Price: $4.40 Points: +91.96 Created: 02/03/2010 SMA20 up to upper BB Comments: 0 | Comment Gritz06 Recs:

BUY: PROGENICS PHARMACEUTICALS INC. (PGNX) Start Price: $23.56 Points: -52.26 Created: 01/01/2008 Comments: 0 | Comment frohos Recs:

BUY: PROGENICS PHARMACEUTICALS INC. (PGNX) Start Price: $29.75 Points: -60.65 Created: 01/01/2008 Comments: 0 | Comment RightPassive Recs:

BUY: PROGENICS PHARMACEUTICALS INC. (PGNX) Start Price: $29.70 Points: -60.60 Created: 01/01/2008 Comments: 0 | Comment JohnnyRoberts Recs:

BUY: PROGENICS PHARMACEUTICALS INC. (PGNX) Start Price: $26.80 Points: -57.14 Created: 01/01/2008 Comments: 0 | Comment lovinguy71 Recs:

BUY: PROGENICS PHARMACEUTICALS INC. (PGNX) Start Price: $28.97 Points: -59.79 Created: 01/01/2008 Comments: 0 | Comment Misha Recs:

BUY: PROGENICS PHARMACEUTICALS INC. (PGNX) Start Price: $27.00 Points: -57.40 Created: 01/01/2008 Comments: 0 | Comment Lance Recs:

BUY: PROGENICS PHARMACEUTICALS INC. (PGNX) Start Price: $28.97 Points: -59.79 Created: 01/01/2008 Comments: 0 | Comment ARUSA Recs:

BUY: PROGENICS PHARMACEUTICALS INC. (PGNX) Start Price: $29.74 Points: -60.64 Created: 01/01/2008 Comments: 0 | Comment MJKRacing Recs:

BUY: PROGENICS PHARMACEUTICALS INC. (PGNX) Start Price: $29.70 Points: -60.60 Created: 01/01/2008 Comments: 0 | Comment gr00ve Recs:

Pages: [ 1 ]  2  >>

Picks

Username	P&P Score	Call	Time Frame	Start Date	Start Price	Today (change)	Stock Gain	S&P Gain	Points	Analysis
Yade	99.86	BUY	One to Three Years	12/22/2011	$9.05	$9.49 (+0.16%)	+4.92%	+8.36%	-3.44
Gritz06	53.29	BUY	Week to a Month	02/03/2010	$4.40	$9.49 (+0.16%)	+115.80%	+23.84%	+91.96	view close
frohos	41.45	BUY	Six Months to a Year	01/01/2008	$23.56	$9.49 (+0.16%)	-59.70%	-7.43%	-52.26
RightPassive	23.11	BUY	Six Months to a Year	01/01/2008	$29.75	$9.49 (+0.16%)	-68.08%	-7.43%	-60.65
JohnnyRoberts	54.56	BUY	Six Months to a Year	01/01/2008	$29.70	$9.49 (+0.16%)	-68.03%	-7.43%	-60.60
lovinguy71	28.47	BUY	Six Months to a Year	01/01/2008	$26.80	$9.49 (+0.16%)	-64.57%	-7.43%	-57.14
Misha	22.60	BUY	Six Months to a Year	01/01/2008	$28.97	$9.49 (+0.16%)	-67.22%	-7.43%	-59.79
Lance	72.12	BUY	Six Months to a Year	01/01/2008	$27.00	$9.49 (+0.16%)	-64.83%	-7.43%	-57.40
ARUSA	59.56	BUY	Six Months to a Year	01/01/2008	$28.97	$9.49 (+0.16%)	-67.22%	-7.43%	-59.79
MJKRacing	45.98	BUY	Six Months to a Year	01/01/2008	$29.74	$9.49 (+0.16%)	-68.07%	-7.43%	-60.64

Pages: [ 1 ]  2  >>